Frontiers in Oncology (Aug 2021)
Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer
- Xiaoxi Dong,
- Tiantian Zheng,
- Minhua Zhang,
- Chao Dai,
- Lili Wang,
- Lei Wang,
- Ruipeng Zhang,
- Yuan Long,
- Danyi Wen,
- Feng Xie,
- Yue Zhang,
- Yong Huang,
- Jianguo Dong,
- Huan Liu,
- Pan Du,
- Bonnie L. King,
- Winston Tan,
- Shidong Jia,
- Chris X. Lu,
- Manish Kohli,
- Haitao Wang,
- Jianjun Yu
Affiliations
- Xiaoxi Dong
- Predicine Inc., Hayward, CA, United States
- Tiantian Zheng
- Predicine Inc., Hayward, CA, United States
- Minhua Zhang
- Department of Translational Medicine, Laekna Therapeutics Shanghai Co., Ltd., Shanghai, China
- Chao Dai
- Predicine Inc., Hayward, CA, United States
- Lili Wang
- Department of Oncology, Second Hospital of Tianjin Medical University, Tianjin, China
- Lei Wang
- Department of Oncology, Second Hospital of Tianjin Medical University, Tianjin, China
- Ruipeng Zhang
- Department of Translational Medicine, Laekna Therapeutics Shanghai Co., Ltd., Shanghai, China
- Yuan Long
- Department of New Assay Development, Shanghai Lide Biotech Co., Ltd., Shanghai, China
- Danyi Wen
- Shanghai Lide Biotech Co., Ltd., Shanghai, China
- Feng Xie
- Huidu Shanghai Medical Sciences Ltd., Shanghai, China
- Yue Zhang
- Huidu Shanghai Medical Sciences Ltd., Shanghai, China
- Yong Huang
- Huidu Shanghai Medical Sciences Ltd., Shanghai, China
- Jianguo Dong
- Huidu Shanghai Medical Sciences Ltd., Shanghai, China
- Huan Liu
- Department of Biology, Shanghai Lide Biotech Co., Ltd., Shanghai, China
- Pan Du
- Predicine Inc., Hayward, CA, United States
- Bonnie L. King
- Predicine Inc., Hayward, CA, United States
- Winston Tan
- Division of Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, United States
- Shidong Jia
- Predicine Inc., Hayward, CA, United States
- Chris X. Lu
- Laekna Therapeutics Shanghai Co., Ltd., Shanghai, China
- Manish Kohli
- 0Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States
- Haitao Wang
- Department of Oncology, Second Hospital of Tianjin Medical University, Tianjin, China
- Jianjun Yu
- Predicine Inc., Hayward, CA, United States
- DOI
- https://doi.org/10.3389/fonc.2021.720727
- Journal volume & issue
-
Vol. 11
Abstract
Current liquid biopsy assays lack sufficient sensitivity to detect copy number loss, which limits the interrogation of critical tumor suppressor gene deletions during cancer progression and treatment. Here we describe a liquid biopsy assay with improved sensitivity for detection of copy number loss in blood samples with low levels of circulating tumor DNA, and demonstrate its utility by profiling PTEN, RB1, and TP53 genetic loss in metastatic prostate cancer patients.
Keywords
